Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 30, 2026, 8:24 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 49–72 of 334 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Moderate Psoriasis Clear all
Completed Phase 2 Interventional

A Study of R3421 in Patients With Moderate to Severe Chronic Plaque Psoriasis.

NCT00504270
View directory record Official record
Conditions
Psoriasis
Interventions
Placebo, RG3421 120mg, RG3421 20mg
Drug
Lead sponsor
Hoffmann-La Roche
Industry
Eligibility
18 Years to 70 Years
Enrollment
66 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2009
U.S. locations
15
States / cities
Hot Springs, Arkansas • Little Rock, Arkansas • Santa Monica, California + 11 more
Source: ClinicalTrials.gov public record
Updated Nov 2, 2016 · Synced Oct 30, 2026, 8:24 PM EDT
Completed Phase 2 Interventional Results available

An Efficacy and Safety Study of LYC-30937-EC in Subjects With Moderate Chronic Plaque-type Psoriasis

NCT02872285
View directory record Official record
Conditions
Psoriasis
Interventions
Drug: LYC-30937-EC, Placebo
Drug
Lead sponsor
Lycera Corp.
Industry
Eligibility
18 Years to 75 Years
Enrollment
33 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2017
U.S. locations
7
States / cities
Carmel, Indiana • Andover, Massachusetts • Fridley, Minnesota + 4 more
Source: ClinicalTrials.gov public record
Updated Apr 10, 2019 · Synced Oct 30, 2026, 8:24 PM EDT
Completed Phase 3 Interventional Results available

A Study of the Safety and Efficacy of Risankizumab in Adult Participants With Plaque Psoriasis Who Have Had a Suboptimal Response to Secukinumab or Ixekizumab

NCT04102007
View directory record Official record
Conditions
Plaque Psoriasis
Interventions
Risankizumab
Drug
Lead sponsor
AbbVie
Industry
Eligibility
18 Years and older
Enrollment
244 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2022
U.S. locations
20
States / cities
Phoenix, Arizona • Hot Springs, Arkansas • North Little Rock, Arkansas + 16 more
Source: ClinicalTrials.gov public record
Updated Nov 27, 2023 · Synced Oct 30, 2026, 8:24 PM EDT
Recruiting Not applicable Interventional

Creating Health Course Study for People With Rheumatological Conditions and Mood Disorders

NCT07180537
View directory record Official record
Conditions
Rheumatoid Arthritis, Sjogren's Syndrome, Systemic Lupus Erythematosus, Mixed Connective Tissue Disease, Psoriatic Arthritis, Anxiety Disorders, Depressive Disorders, Moderate Depression, Moderate Anxiety
Interventions
Creating Health Online Course, Delayed access to Creating Health Online Course
Behavioral
Lead sponsor
Terry L. Wahls
Other
Eligibility
18 Years to 100 Years
Enrollment
400 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
1
States / cities
Iowa City, Iowa
Source: ClinicalTrials.gov public record
Updated Aug 10, 2026 · Synced Oct 30, 2026, 8:24 PM EDT
Recruiting Phase 3 Interventional

A Study to Evaluate the Efficacy, Safety, and Drug Levels of Deucravacitinib (BMS-986165) in Adolescent Participants With Moderate to Severe Plaque Psoriasis

NCT06979453
View directory record Official record
Conditions
Plaque Psoriasis
Interventions
Deucravacitinib, Placebo
Drug · Other
Lead sponsor
Bristol-Myers Squibb
Industry
Eligibility
12 Years to 17 Years
Enrollment
366 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2034
U.S. locations
47
States / cities
Birmingham, Alabama • Phoenix, Arizona • Fountain Valley, California + 40 more
Source: ClinicalTrials.gov public record
Updated Oct 27, 2026 · Synced Oct 30, 2026, 8:24 PM EDT
Completed Phase 2 Interventional Results available

Rimegepant in Moderate Plaque-type Psoriasis

NCT04629950
View directory record Official record
Conditions
Psoriasis
Interventions
Rimegepant, Placebo
Drug
Lead sponsor
Weill Medical College of Cornell University
Other
Eligibility
18 Years to 75 Years
Enrollment
41 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2024
U.S. locations
2
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Jul 17, 2025 · Synced Oct 30, 2026, 8:24 PM EDT
Completed Phase 2 Interventional Results available

A Study of JNJ-77242113 in Participants With Moderate-to-severe Plaque Psoriasis

NCT05223868
View directory record Official record
Conditions
Plaque Psoriasis
Interventions
JNJ-77242113, Placebo
Drug
Lead sponsor
Janssen Research & Development, LLC
Industry
Eligibility
18 Years and older
Enrollment
255 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022
U.S. locations
21
States / cities
Phoenix, Arizona • Sacramento, California • Ocala, Florida + 18 more
Source: ClinicalTrials.gov public record
Updated Feb 13, 2026 · Synced Oct 30, 2026, 8:24 PM EDT
Completed Phase 2 Interventional Results available

Effectiveness and Safety of 3 Dosing Regimens of CP-690,550 to Placebo in Subjects With Moderate to Severe Chronic Plaque Psoriasis

NCT00678210
View directory record Official record
Conditions
Psoriasis
Interventions
CP-690,550, Placebo
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years and older
Enrollment
197 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2009
U.S. locations
29
States / cities
Tucson, Arizona • Little Rock, Arkansas • Oceanside, California + 23 more
Source: ClinicalTrials.gov public record
Updated Dec 19, 2012 · Synced Oct 30, 2026, 8:24 PM EDT
Terminated Phase 2 Interventional Results available

Study to Evaluate the Safety and Efficacy of JTE-051 in Subjects With Moderate to Severe Plaque Psoriasis

NCT03358290
View directory record Official record
Conditions
Plaque Psoriasis, Skin Diseases
Interventions
JTE-051, Placebo
Drug
Lead sponsor
Shionogi Inc.
Industry
Eligibility
18 Years to 70 Years
Enrollment
13 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2018
U.S. locations
12
States / cities
Fountain Valley, California • Fremont, California • Tampa, Florida + 9 more
Source: ClinicalTrials.gov public record
Updated Aug 6, 2021 · Synced Oct 30, 2026, 8:24 PM EDT
Completed Phase 2 Interventional Results available

A Phase 2 Study Investigating the Effect of EDP1815 in the Treatment of Mild to Moderate Plaque Psoriasis

NCT04603027
View directory record Official record
Conditions
Psoriasis, Plaque Psoriasis
Interventions
EDP1815, Placebo
Drug
Lead sponsor
Evelo Biosciences, Inc.
Industry
Eligibility
18 Years to 70 Years
Enrollment
249 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2021
U.S. locations
8
States / cities
Santa Rosa, California • Orlando, Florida • St. Petersburg, Florida + 5 more
Source: ClinicalTrials.gov public record
Updated Dec 19, 2022 · Synced Oct 30, 2026, 8:24 PM EDT
Completed Phase 2 Interventional Results available

Study To Assess Efficacy, Safety, Tolerability And Pharmacokinetics Of PF-07038124 Ointment In Participants With Atopic Dermatitis Or Plaque Psoriasis

NCT04664153
View directory record Official record
Conditions
Atopic Dermatitis, Plaque Psoriasis
Interventions
PF-07038124 ointment, Vehicle ointment
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years to 70 Years
Enrollment
104 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2021
U.S. locations
15
States / cities
Fountain Valley, California • Cape Coral, Florida • Clearwater, Florida + 12 more
Source: ClinicalTrials.gov public record
Updated Aug 26, 2022 · Synced Oct 30, 2026, 8:24 PM EDT
Completed Phase 2 Interventional Results available

A Study of LY4100511 (DC-853) in Adult Participants With Moderate-to-Severe Plaque Psoriasis

NCT06602219
View directory record Official record
Conditions
Plaque Psoriasis
Interventions
LY4100511, Placebo
Drug
Lead sponsor
DICE Therapeutics, Inc., a wholly owned subsidiary of Eli Lilly and Company
Industry
Eligibility
18 Years to 70 Years
Enrollment
222 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2025
U.S. locations
15
States / cities
Birmingham, Alabama • Bryant, Arkansas • Beverly Hills, California + 12 more
Source: ClinicalTrials.gov public record
Updated Aug 18, 2026 · Synced Oct 30, 2026, 8:24 PM EDT
Completed Phase 3 Interventional Results available

Efficacy and Safety Study of Apremilast (CC-10004) in Pediatric Subjects From 6 Through 17 Years of Age With Moderate to Severe Plaque Psoriasis

NCT03701763
View directory record Official record
Conditions
Psoriasis
Interventions
Apremilast (CC-10004), Placebo
Drug · Other
Lead sponsor
Amgen
Industry
Eligibility
6 Years to 17 Years
Enrollment
245 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2023
U.S. locations
39
States / cities
Birmingham, Alabama • Phoenix, Arizona • Fort Smith, Arkansas + 35 more
Source: ClinicalTrials.gov public record
Updated Dec 16, 2024 · Synced Oct 30, 2026, 8:24 PM EDT
Completed Phase 1 Interventional

Topically Applied IDP-118 Lotion and HP Monad Lotion in Subjects With Moderate to Severe Plaque Psoriasis

NCT03058744
View directory record Official record
Conditions
Psoriasis
Interventions
IDP-118 Lotion, HP Monad Lotion, Ultravate Cream, Tazorac Cream
Drug
Lead sponsor
Bausch Health Americas, Inc.
Industry
Eligibility
18 Years and older
Enrollment
94 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2017
U.S. locations
12
States / cities
Anaheim, California • Encino, California • San Diego, California + 9 more
Source: ClinicalTrials.gov public record
Updated Jun 9, 2017 · Synced Oct 30, 2026, 8:24 PM EDT
Completed Phase 3 Interventional Results available

A Study of Guselkumab in the Treatment of Participants With Moderate to Severe Plaque-Type Psoriasis With Randomized Withdrawal and Retreatment

NCT02207244
View directory record Official record
Conditions
Psoriasis
Interventions
Guselkumab 100 mg, Placebo for guselkumab, Adalimumab, Placebo for adalimumab
Drug
Lead sponsor
Janssen Research & Development, LLC
Industry
Eligibility
18 Years to 99 Years
Enrollment
992 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2020
U.S. locations
32
States / cities
Birmingham, Alabama • Bakersfield, California • Los Angeles, California + 29 more
Source: ClinicalTrials.gov public record
Updated Jul 22, 2021 · Synced Oct 30, 2026, 8:24 PM EDT
Completed Phase 3 Interventional Results available

A Study to Assess Usability of Risankizumab Autoinjector Combination Product in Participants With Moderate to Severe Plaque Psoriasis

NCT03875508
View directory record Official record
Conditions
Psoriasis
Interventions
Risankizumab, Autoinjector
Drug · Device
Lead sponsor
AbbVie
Industry
Eligibility
18 Years and older
Enrollment
108 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2020
U.S. locations
26
States / cities
Glendale, Arizona • Scottsdale, Arizona • Hot Springs, Arkansas + 22 more
Source: ClinicalTrials.gov public record
Updated May 11, 2021 · Synced Oct 30, 2026, 8:24 PM EDT
Completed Phase 2 Interventional Results available

A Trial of a Botanical Drug (EISO) for Treatment of Mild-to-Moderate Plaque Psoriasis

NCT03000608
View directory record Official record
Conditions
Plaque Psoriasis
Interventions
SAN021 Serum, SAN021 Placebo
Drug
Lead sponsor
Santalis Pharmaceuticals, Inc.
Industry
Eligibility
18 Years to 65 Years
Enrollment
69 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017
U.S. locations
4
States / cities
Austin, Texas • San Antonio, Texas
Source: ClinicalTrials.gov public record
Updated May 29, 2019 · Synced Oct 30, 2026, 8:24 PM EDT
Terminated Phase 1 Interventional

Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Clinical Effects of AMG 557 in Adults With Psoriasis

NCT01493518
View directory record Official record
Conditions
Psoriasis
Interventions
AMG 557 or PLACEBO
Drug
Lead sponsor
Amgen
Industry
Eligibility
18 Years to 55 Years
Enrollment
6 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2013
U.S. locations
6
States / cities
Birmingham, Alabama • Reno, Nevada • Portland, Oregon + 2 more
Source: ClinicalTrials.gov public record
Updated Nov 19, 2013 · Synced Oct 30, 2026, 8:24 PM EDT
Completed Phase 3 Interventional Results available

A Study of Ixekizumab (LY2439821) in Participants With Moderate-to-Severe Genital Psoriasis

NCT02718898
View directory record Official record
Conditions
Genital Psoriasis, Psoriasis
Interventions
Ixekizumab, Placebo
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
18 Years and older
Enrollment
149 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2018
U.S. locations
13
States / cities
Santa Ana, California • Santa Monica, California • Tampa, Florida + 9 more
Source: ClinicalTrials.gov public record
Updated Sep 16, 2019 · Synced Oct 30, 2026, 8:24 PM EDT
Completed Phase 3 Interventional Results available

A Study to Evaluate the Efficacy and Safety of Bimekizumab in Adult Subjects With Moderate to Severe Chronic Plaque Psoriasis

NCT03412747
View directory record Official record
Conditions
Chronic Plaque Psoriasis, Moderate to Severe Plaque Psoriasis
Interventions
Bimekizumab, Adalimumab, Placebo
Drug · Other
Lead sponsor
UCB Biopharma SRL
Industry
Eligibility
18 Years and older
Enrollment
478 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2020
U.S. locations
23
States / cities
Glendale, Arizona • Los Angeles, California • San Diego, California + 19 more
Source: ClinicalTrials.gov public record
Updated Apr 15, 2026 · Synced Oct 30, 2026, 8:24 PM EDT
Completed Phase 3 Interventional Results available

Study to Demonstrate Equivalent Efficacy and to Compare Safety of Biosimilar Adalimumab (GP2017) and Humira

NCT02016105
View directory record Official record
Conditions
Plaque Type Psoriasis
Interventions
GP2017 Adalimumab, Humira ® Adalimumab
Drug
Lead sponsor
Sandoz
Industry
Eligibility
18 Years and older
Enrollment
465 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2016
U.S. locations
69
States / cities
Birmingham, Alabama • Phoenix, Arizona • Hot Springs, Arkansas + 60 more
Source: ClinicalTrials.gov public record
Updated May 30, 2017 · Synced Oct 30, 2026, 8:24 PM EDT
Completed Phase 3 Interventional Results available

A Study to Evaluate the Efficacy and Safety of Bimekizumab Compared to an Active Comparator in Adult Subjects With Moderate to Severe Chronic Plaque Psoriasis

NCT03536884
View directory record Official record
Conditions
Chronic Plaque Psoriasis, Moderate to Severe Chronic Plaque Psoriasis
Interventions
Bimekizumab, Secukinumab, Placebo
Drug · Other
Lead sponsor
UCB Biopharma SRL
Industry
Eligibility
18 Years and older
Enrollment
743 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2023
U.S. locations
25
States / cities
Santa Ana, California • Danbury, Connecticut • Ocala, Florida + 20 more
Source: ClinicalTrials.gov public record
Updated Apr 15, 2026 · Synced Oct 30, 2026, 8:24 PM EDT
Completed Phase 2 Interventional Results available

Efficacy and Safety of ME3183 in Subjects With Moderate to Severe Plaque Psoriasis

NCT05268016
View directory record Official record
Conditions
Plaque Psoriasis
Interventions
ME3183, Placebo
Drug
Lead sponsor
Meiji Pharma USA Inc.
Industry
Eligibility
18 Years to 75 Years
Enrollment
132 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2023
U.S. locations
14
States / cities
Rogers, Arkansas • Los Angeles, California • Denver, Colorado + 11 more
Source: ClinicalTrials.gov public record
Updated Jun 27, 2024 · Synced Oct 30, 2026, 8:24 PM EDT
Completed Phase 3 Interventional Results available

A Study to Evaluate the Safe and Effective Use of the Prefilled Safety Syringe or the Auto-injector for the Subcutaneous Self-injection of Bimekizumab Solution by Subjects With Moderate to Severe Chronic Plaque Psoriasis (PSO)

NCT03766685
View directory record Official record
Conditions
Chronic Plaque Psoriasis, Moderate to Severe Chronic Plaque Psoriasis
Interventions
Bimekizumab
Drug
Lead sponsor
UCB Biopharma SRL
Industry
Eligibility
18 Years and older
Enrollment
172 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2020
U.S. locations
27
States / cities
Phoenix, Arizona • Bakersfield, California • San Diego, California + 23 more
Source: ClinicalTrials.gov public record
Updated Jul 14, 2025 · Synced Oct 30, 2026, 8:24 PM EDT